WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that nine presentations – one oral and eight poster presentations – will be given by ImmunoGen scientists at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, April 2-6, 2011.
